Clinical Trials Browser

Recruiting × Leukemia, Myeloid, Accelerated Phase × 30 days × Clear all

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT03263572 2026-05-20

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Phase 2 Recruiting

90 enrolled

LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05794880 2026-05-13

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Phase NA Recruiting

40 enrolled

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Personalized NK Cell Therapy in CBT

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing